JP Morgan Maintains Neutral on Chemours, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 75.8%

Neg 75.8% Neu 0% Pos 0%

JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $22 to $15.